ITMI20011483A0 - USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL CANNABINOID RECEPTORS - Google Patents

USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL CANNABINOID RECEPTORS

Info

Publication number
ITMI20011483A0
ITMI20011483A0 IT2001MI001483A ITMI20011483A ITMI20011483A0 IT MI20011483 A0 ITMI20011483 A0 IT MI20011483A0 IT 2001MI001483 A IT2001MI001483 A IT 2001MI001483A IT MI20011483 A ITMI20011483 A IT MI20011483A IT MI20011483 A0 ITMI20011483 A0 IT MI20011483A0
Authority
IT
Italy
Prior art keywords
compounds
cannabinoid receptors
functional antagonists
central cannabinoid
central
Prior art date
Application number
IT2001MI001483A
Other languages
Italian (it)
Inventor
Alberta Leon
Carbonare Maurizio Dalle
Original Assignee
Res & Innovation Soc Coop A R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res & Innovation Soc Coop A R filed Critical Res & Innovation Soc Coop A R
Priority to IT2001MI001483A priority Critical patent/ITMI20011483A1/en
Publication of ITMI20011483A0 publication Critical patent/ITMI20011483A0/en
Priority to PCT/EP2002/007722 priority patent/WO2003006007A1/en
Priority to EP02764671A priority patent/EP1425004A1/en
Publication of ITMI20011483A1 publication Critical patent/ITMI20011483A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
IT2001MI001483A 2001-07-11 2001-07-11 USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS ITMI20011483A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT2001MI001483A ITMI20011483A1 (en) 2001-07-11 2001-07-11 USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS
PCT/EP2002/007722 WO2003006007A1 (en) 2001-07-11 2002-07-11 Use of compounds as functional antagonists to the central cannabinoid receptors
EP02764671A EP1425004A1 (en) 2001-07-11 2002-07-11 Use of compounds as functional antagonists to the central cannabinoid receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001483A ITMI20011483A1 (en) 2001-07-11 2001-07-11 USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS

Publications (2)

Publication Number Publication Date
ITMI20011483A0 true ITMI20011483A0 (en) 2001-07-11
ITMI20011483A1 ITMI20011483A1 (en) 2003-01-11

Family

ID=11448045

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001MI001483A ITMI20011483A1 (en) 2001-07-11 2001-07-11 USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS

Country Status (3)

Country Link
EP (1) EP1425004A1 (en)
IT (1) ITMI20011483A1 (en)
WO (1) WO2003006007A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910393D0 (en) 1999-05-05 1999-07-07 Lucas Ind Plc Electrical generator,an aero-engine including such a generator and an aircraft including such a generator
ATE486842T1 (en) 2002-03-12 2010-11-15 Merck Sharp & Dohme SUBSTITUTED AMIDES
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CA2499497A1 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ITMI20030210A1 (en) * 2003-02-07 2004-08-08 Res & Innovation Soc Coop A R L ENDOCANNABINOID-SIMILAR COMPOUNDS AND THEIR USE
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
FR2851460B1 (en) * 2003-02-21 2007-05-11 Seppic Sa USE OF N-LAUROYL AMINOACIDS AS A SLIMMING COSMETIC AND PHARMACEUTICAL ACTIVE
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
ATE547404T1 (en) 2003-09-22 2012-03-15 Msd Kk PIPERIDINE DERIVATIVES
AU2004287849A1 (en) 2003-10-30 2005-05-19 Merck Sharp & Dohme Corp. Aralkyl amines as cannabinoid receptor modulators
JP2007522118A (en) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー Therapeutic and carrier molecules
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
BRPI0618354B8 (en) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd compound and its use, pharmaceutical composition, preventive or medicine
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
ES2620285T3 (en) 2008-05-02 2017-06-28 Novartis Ag Binding molecules based on improved fibronectin and their uses
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
MX2011004258A (en) 2008-10-22 2011-06-01 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
ES2659406T3 (en) 2010-05-06 2018-03-15 Novartis Ag Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6)
CN103080134B (en) 2010-08-20 2015-11-25 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
KR20150075120A (en) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2773669B1 (en) 2011-11-04 2018-03-28 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
JP6243345B2 (en) 2011-12-05 2017-12-06 ノバルティス アーゲー Antibody to epidermal growth factor receptor 3 (HER3)
KR20140103135A (en) 2011-12-05 2014-08-25 노파르티스 아게 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
KR20150118158A (en) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 Antidiabetic bicyclic compounds
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6458809B2 (en) 2014-04-25 2019-01-30 味の素株式会社 Immunostimulator
EP3368508A1 (en) 2015-10-28 2018-09-05 Ajinomoto Co., Inc. Immunostimulating agent
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
CN110590855B (en) * 2016-01-25 2023-05-12 沈阳药科大学 Preparation method of platinum complex, liposome containing platinum complex and preparation method of liposome
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018132876A1 (en) * 2017-01-19 2018-07-26 The University Of Sydney Novel glycine transport inhibitors for the treatment of pain
US11324709B2 (en) * 2017-05-22 2022-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fatty acid amides and uses thereof in the treatment of addiction disorder and addiction related conditions
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
EP3887393A1 (en) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusion polypeptides
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271623B (en) * 1994-03-21 1997-06-04 Lifegroup Spa N-ACYL DERIVATIVES OF AMINO-ALCOHOLS WITH MONOCARBOSSYL AND BICARBOSSYLIC ACIDS WITH NEUROPROTECTIVE ACTIVITY IN NEUROLOGICAL DISEASES RELATED TO EXCITOTOXICITY
IT1271266B (en) * 1994-12-14 1997-05-27 Valle Francesco Della THERAPEUTIC USE OF MONO AND BICARBOXYLIC ACID AMIDES WITH AMINO ALCOHOLS, SELECTIVELY ACTIVE ON THE PERIPHERAL RECEPTOR OF CANNABINOIDS
IT1271267B (en) * 1994-12-14 1997-05-27 Valle Francesco Della MONO AND BICARBOXYLIC ACID AMIDES WITH AMINO ALCOHOLS, SELECTIVELY ACTIVE ON THE PERIPHERAL RECEPTOR OF CANNABINOIDS

Also Published As

Publication number Publication date
ITMI20011483A1 (en) 2003-01-11
WO2003006007A1 (en) 2003-01-23
EP1425004A1 (en) 2004-06-09

Similar Documents

Publication Publication Date Title
ITMI20011483A0 (en) USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL CANNABINOID RECEPTORS
ZA200408335B (en) Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors.
ATE525378T1 (en) HIMBACIN ANALOGS AS THROMBIN RECEPTOR ANTAGONISTS
ATE420083T1 (en) UREA DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS FOR PAIN TREATMENT
ATE374191T1 (en) UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS
HK1081449A1 (en) Pharmaceutical compositions directed to erb-b1 receptors
DE60216229D1 (en) IL-8 receptor antagonists
DE602005013675D1 (en) INDOL-2-CARBOXAMIDINE DERIVATIVES AS ANTAGONISTS OF NMDA RECEPTORS
BR0206595A (en) Compound, pharmaceutical composition, and use of a compound
DE60226161D1 (en) 3-AZABICYCLO (3.1.0) HEXAN DERIVATIVE AS ANTAGONISTS OF OPIOID RECEPTORS
ITMI20020281A1 (en) CYCLIC PHOSFAZENIC COMPOUNDS AND THEIR USE AS ADDITIVES OF PERFLUOROPOLYEREAL OILS
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
ATE492535T1 (en) 4-PIPERIDINYLALKYLAMIN DERIVATIVES, ANTAGONISTS OF MUSCARIINE RECEPTORS
DE60224221D1 (en) AMINOTETRALIN DERIVATIVES, ANTAGONISTS OF MUSCARIN RECEPTORS
EE200200667A (en) Bicyclic cyclohexylamines and their use as NMDA receptor antagonists
EE04439B1 (en) 5HT1 antagonists for antidepressant therapy
ATE365455T1 (en) AMINOACETONITRIL COMPOUNDS TO FIGHT ENDOPARASITES
ATE244716T1 (en) NEW N-TRIAZOLYLMETHYL-PIPERAZINE DERIVATIVES AS NEUROKININE RECEPTOR ANTAGONISTS
ATE394114T1 (en) SOMATOSTATIN ANTAGONISTS
DE50206910D1 (en) SUBSTITUTED Y-LACTON COMPOUNDS AS NMDA ANTAGONISTS
DE60210058D1 (en) ALKOXYCARBONYLAMINO-HETEROARYL CARBOXYLENE DERIVATIVES AS IP ANTAGONISTS
ATE441642T1 (en) HYDANTOIN DERIVATIVES WITH AFFINITY FOR SOMATOSTATIN RECEPTORS
DK1261588T3 (en) Imidazole compounds as alpha2-adrenoceptor antagonists
ATE504300T1 (en) UREA DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS
IT1317861B1 (en) USE OF FLUORINATED COMPOUNDS TO PROVIDE RELEASE PROPERTIES.